Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials
- PMID: 25703886
- DOI: 10.1016/j.jcin.2014.09.023
Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials
Abstract
Objectives: A Bayesian network meta-analysis was performed comparing the efficacy and safety of drug-eluting balloons (DEB), drug-eluting stents (DES), or plain old balloon angioplasty (POBA) for treatment of in-stent restenosis (ISR).
Background: Optimal treatment options for ISR have not been well established.
Methods: Randomized, controlled trials comparing DEB, DES, and POBA for the treatment of ISR after percutaneous coronary intervention with bare metal stent or DES were included. The primary outcome was target lesion revascularization (TLR). The pairwise posterior median odds ratio (OR) with 95% credible interval (CrI) was the effect measure.
Results: This analysis included 2,059 patients from 11 RCTs. The risk of TLR was markedly lower in patients treated with DEB (OR: 0.22, 95% CrI: 0.10 to 0.42) or DES (OR: 0.24, 95% CrI: 0.11 to 0.47) than in those treated with POBA in a random-effects model. In a comparison of DEB and DES, the risk of TLR (OR: 0.92, 95% CrI: 0.43 to 1.90) was similar. The risk of MI or all-cause mortality was lowest in the DEB group compared with the DES and POBA groups, which did not meet statistical significance. The risk of major adverse cardiac events, which was mainly driven by TLR, was also significantly lower in the DEB or and DES group (OR: 0.28, 95% CrI: 0.14 to 0.53) than in the POBA group, but it was similar between the DEB and DES groups (OR: 0.84, 95% CrI: 0.45 to 1.50). The probability of being ranked as the best treatment was 59.9% (DEB), 40.1% (DES), and 0.1% (POBA) in terms of TLR, whereas it was 63.0% (DEB), 35.3% (POBA), and 1.7% (DES) in terms of MI.
Conclusions: Local drug delivery by DEB or DES for ISR lesions was markedly better than POBA in preventing TLR, but not for MI or mortality. Among the 2 different strategies of drug delivery for ISR lesions, treatment with DEB showed a trend of less development of MI than did treatment with DES.
Keywords: controlled trial; drug-eluting balloons; drug-eluting stents; in-stent restenosis; meta-analysis; randomized.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Do we know the best treatment for in-stent restenosis via network meta-analysis (NMA)?: simple methods any interventionalist can use to assess NMA quality and a call for better NMA presentation.JACC Cardiovasc Interv. 2015 Mar;8(3):395-397. doi: 10.1016/j.jcin.2014.11.012. Epub 2015 Feb 18. JACC Cardiovasc Interv. 2015. PMID: 25703877 No abstract available.
Similar articles
-
Drug-Eluting Balloon versus New-Generation Drug-Eluting Stent for the Treatment of In-Stent Restenosis: An Updated Systematic Review and Meta-Analysis.Chin Med J (Engl). 2018 Mar 5;131(5):600-607. doi: 10.4103/0366-6999.226073. Chin Med J (Engl). 2018. PMID: 29483397 Free PMC article.
-
Drug-eluting balloon versus bare-mental stent and drug-eluting stent for de novo coronary artery disease: A systematic review and meta-analysis of 14 randomized controlled trials.PLoS One. 2017 Apr 26;12(4):e0176365. doi: 10.1371/journal.pone.0176365. eCollection 2017. PLoS One. 2017. PMID: 28445555 Free PMC article.
-
Comparative Effectiveness of Plain Balloon Angioplasty, Bare Metal Stents, Drug-Coated Balloons, and Drug-Eluting Stents for the Treatment of Infrapopliteal Artery Disease: Systematic Review and Bayesian Network Meta-analysis of Randomized Controlled Trials.J Endovasc Ther. 2016 Dec;23(6):851-863. doi: 10.1177/1526602816671740. Epub 2016 Oct 5. J Endovasc Ther. 2016. PMID: 27708143
-
Management of drug eluting stent in-stent restenosis: A systematic review and meta-analysis.Catheter Cardiovasc Interv. 2016 May;87(6):1080-91. doi: 10.1002/ccd.26151. Epub 2015 Nov 28. Catheter Cardiovasc Interv. 2016. PMID: 26613637
-
Comparing the Efficacy of Sirolimus and Paclitaxel-Eluting Balloon Catheters in the Treatment of Coronary In-Stent Restenosis: A Prospective Randomized Study (TIS 2 Study).Circ Cardiovasc Interv. 2025 May;18(5):e014677. doi: 10.1161/CIRCINTERVENTIONS.124.014677. Epub 2025 Apr 2. Circ Cardiovasc Interv. 2025. PMID: 40171676 Clinical Trial.
Cited by
-
Radiofrequency Ablation of the Atherosclerotic Plaque: a Proof of Concept Study in an Atherosclerotic Model.J Cardiovasc Transl Res. 2017 Apr;10(2):221-232. doi: 10.1007/s12265-017-9743-3. Epub 2017 Mar 31. J Cardiovasc Transl Res. 2017. PMID: 28364193 Free PMC article.
-
Network meta-analyses on in-stent restenosis treatment: dealing with complexity to clarify efficacy and safety.J Thorac Dis. 2015 Oct;7(10):1678-83. doi: 10.3978/j.issn.2072-1439.2015.10.15. J Thorac Dis. 2015. PMID: 26623081 Free PMC article. No abstract available.
-
Drug-Eluting Balloon versus New-Generation Drug-Eluting Stent for the Treatment of In-Stent Restenosis: An Updated Systematic Review and Meta-Analysis.Chin Med J (Engl). 2018 Mar 5;131(5):600-607. doi: 10.4103/0366-6999.226073. Chin Med J (Engl). 2018. PMID: 29483397 Free PMC article.
-
Treatment of In-Stent Restenosis by Excimer Laser Coronary Atherectomy and Drug-Coated Balloon: Serial Assessment with Optical Coherence Tomography.J Interv Cardiol. 2019 Apr 18;2019:6515129. doi: 10.1155/2019/6515129. eCollection 2019. J Interv Cardiol. 2019. PMID: 31772538 Free PMC article.
-
Intravascular imaging in coronary stent restenosis: Prevention, characterization, and management.Front Cardiovasc Med. 2022 Aug 9;9:843734. doi: 10.3389/fcvm.2022.843734. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36017094 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical